Martin L. Yarmush

Martin L. Yarmush

Auto-generated profile, based on publicly available information

Martin L. Yarmush

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2014 in Annual Review of Biomedical Engineering
Verified
Journal Article
Closed access
MYMartin L. Yarmush
Martin L. Yarmush
AGAlexander Golberg
Alexander Golberg
GSGregor Serša
Gregor Serša
TKTadej Kotnik
Tadej Kotnik
DMDamijan Miklavčič
Damijan Miklavčič
When high-amplitude, short-duration pulsed electric fields are applied to cells and tissues, the permeability of the cell membranes and tissue is increased. This increase in permeability is currently explained by the temporary appearance of aqueous pores within the cell membrane, a phenomenon termed electroporation. During the past four decades, advances in fundamental and experimental electroporation research have allowed for the translation of electroporation-based technologies to the clinic. In this review, we describe the theory and current applications of electroporation in medicine and then discuss current challenges in electroporation research and barriers to a more extensive spread of these clinical applications.

15 July 2011 in Annual Review of Chemical and Biomolecular Engineering
Verified
Journal Article
Closed access
FBFrançois Berthiaume
François Berthiaume
TMTimothy J. Maguire
Timothy J. Maguire
MYMartin L. Yarmush
Martin L. Yarmush
The past three decades have seen the emergence of an endeavor called tissue engineering and regenerative medicine in which scientists, engineers, and physicians apply tools from a variety of fields to construct biological substitutes that can mimic tissues for diagnostic and research purposes and can replace (or help regenerate) diseased and injured tissues. A significant portion of this effort has been translated to actual therapies, especially in the areas of skin replacement and, to a lesser extent, cartilage repair. A good amount of thoughtful work has also yielded prototypes of other tissue substitutes such as nerve conduits, blood vessels, liver, and even heart. Forward movement to clinical product, however, has been slow. Another offshoot of these efforts has been the incorporation of some new exciting technologies (e.g., microfabrication, 3D printing) that may enable future breakthroughs. In this review we highlight the modest beginnings of the field and then describe three application examples that are in various stages of development, ranging from relatively mature (skin) to ongoing proof-of-concept (cartilage) to early stage (liver). We then discuss some of the major issues that limit the development of complex tissues, some of which are fundamentals-based, whereas others stem from the needs of the end users.

1 June 2010 in Cell Transplantation
Verified
Journal Article
Open access
HYHiroshi Yagi
Hiroshi Yagi
ASAlejandro Soto-Gutierrez
Alejandro Soto-Gutierrez
BPBiju Parekkadan
Biju Parekkadan
YKYuko Kitagawa
Yuko Kitagawa
RTRonald G. Tompkins
Ronald G. Tompkins
MYMartin L. Yarmush
Martin L. Yarmush
Mesenchymal stem cell (MSC) transplantation has been explored as a new clinical approach to repair injured tissue. A growing corpus of studies have highlighted two important aspects of MSC therapy: 1) MSCs can modulate T-cell-mediated immunological responses, and ( 2 ) systemically administered MSCs home to sites of ischemia or injury. In this review, we describe the known mechanisms of immunomodulation and homing of MSCs. First, we examine the low immunogenicity of MSCs and their antigen presentation capabilities. Next, we discuss the paracrine interactions between MSCs and innate [dendritic cells (DC)] and adaptive immune cells (T lymphocytes) with a focus on prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and toll-like receptor (TLR) signaling pathways. We transition to outline the steps of activation, rolling/adhesion, and transmigration of MSCs into target tissues during inflammatory or ischemic conditions. These aspects of MSC grafts—immunomodulation and homing—are contextualized to understand a reported side effect of MSC therapy, cancer development.

24 January 2008 in Hepatology
Verified
Journal Article
Open access
PDF file
DPDaan van Poll
Daan van Poll
BPBiju Parekkadan
Biju Parekkadan
CCCheul H. Cho
Cheul H. Cho
FBFrançois Berthiaume
François Berthiaume
YNYaakov Nahmias
Yaakov Nahmias
MYMartin L. Yarmush
Martin L. Yarmush
Orthotopic liver transplantation is the only proven effective treatment for fulminant hepatic failure (FHF), but its use is limited because of organ donor shortage, associated high costs, and the requirement for lifelong immunosuppression. FHF is usually accompanied by massive hepatocellular death with compensatory liver regeneration that fails to meet the cellular losses. Therefore, therapy aimed at inhibiting cell death and stimulating endogenous repair pathways could offer major benefits in the treatment of FHF. Recent studies have demonstrated that mesenchymal stem cell (MSC) therapy can prevent parenchymal cell loss and promote tissue repair in models of myocardial infarction, acute kidney failure, and stroke through the action of trophic secreted molecules. In this study, we investigated whether MSC therapy can protect the acutely injured liver and stimulate regeneration. In a D-galactosamine–induced rat model of acute liver injury, we show that systemic infusion of MSC-conditioned medium (MSC-CM) provides a significant survival benefit and prevents the release of liver injury biomarkers. Furthermore, MSC-CM therapy resulted in a 90% reduction of apoptotic hepatocellular death and a three-fold increment in the number of proliferating hepatocytes. This was accompanied by a dramatic increase in the expression levels of 10 genes known to be up-regulated during hepatocyte replication. Direct antiapoptotic and promitotic effects of MSC-CM on hepatocytes were demonstrated using in vitro assays. Conclusion: These data provide the first clear evidence that MSC-CM therapy provides trophic support to the injured liver by inhibiting hepatocellular death and stimulating regeneration, potentially creating new avenues for the treatment of FHF.

26 September 2007 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BPBiju Parekkadan
Biju Parekkadan
DPDaan van Poll
Daan van Poll
KSKazuhiro Suganuma
Kazuhiro Suganuma
ECEdward A. Carter
Edward A. Carter
FBFrançois Berthiaume
François Berthiaume
MYMartin L. Yarmush
Martin L. Yarmush
Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators in vitro. Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions in vivo. Herein, we report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic modality for FHF.

1 November 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
BPBiju Parekkadan
Biju Parekkadan
DPDaan van Poll
Daan van Poll
ZMZaki Megeed
Zaki Megeed
NKNaoya Kobayashi
Naoya Kobayashi
ATArno W. Tilles
Arno W. Tilles
MYMartin L. Yarmush
Martin L. Yarmush